Meet Codi Darnell: Living that Mom, Wife and Wheelchair Life
By Codi Darnell Nancy Thompson, Interviewer February 2, 2021 Life is unpredictable, but at 28 years old, Codi Darnell felt like she had life figured out. She had an amazing husband, three wonderful children and a great life. Then, in a single moment, everything came crashing down. On March 10, 2016, Codi suffered a fall […]
NervGen Pharma Adds Alzheimer’s Disease Patient Cohort to its Phase 1 Clinical Trial Program
Vancouver, Canada. January 27, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it will add an Alzheimer’s disease patient cohort to its Phase 1 clinical trial program for its lead […]
NervGen Pharma Establishes Alzheimer’s Disease Scientific Advisory Board
Vancouver, Canada. January 26, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the formation of its Alzheimer’s Disease Scientific Advisory Board (“AD-SAB”) with the appointment of four world-class scientists and clinical […]
NervGen to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
Vancouver, Canada, January 5, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that Paul Brennan, President & CEO, will conduct a corporate presentation at the LifeSci Partners 10th Annual Healthcare Corporate […]
NervGen Pharma Engages CRO for Phase 1 Clinical Trial
Vancouver, Canada. December 15, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it has engaged Novotech (Australia) Pty Limited (“Novotech”), a leading full-service contract research organization (“CRO”) in Asia-Pacific, for its upcoming Phase […]
NervGen Pharma Reports Third Quarter 2020 Results and Provides Operational Update
Vancouver, Canada. November 19, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the third quarter ended September 30, 2020. Paul Brennan, NervGen’s President & CEO, stated, “During […]
NervGen Pharma Retains Dr. George Perry to Advise on Alzheimer’s Disease Program / NervGen Renews Business Advisory Relationship with Brian McAlister
Vancouver, Canada. November 10, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it has retained George Perry, PhD, the current and founding Editor-in-Chief of the Journal of Alzheimer’s Disease and Semmes Distinguished University […]
NervGen Pharma Appoints Randall E. Kaye, MD to the Board of Directors and Provides Operational Update
Vancouver, Canada. October 28, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it has appointed Dr. Randall Kaye to the Company’s Board of Directors. Separately, NervGen announced that they were advised by its […]
NervGen Pharma Engages Dr. Michael Davis, Former Director of the U.S. Combat Casualty Care Research Program, to Advise on Strategic Development Targets and Non-dilutive Funding Sources for NVG-291
Vancouver, Canada. October 19, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today is pleased to announce that it has retained the services of Michael Davis, MD, FACS, FRCS (Hon.), Colonel (Ret.), formerly […]
NervGen Pharma Provides Company Update and Announces Results of Annual General Meeting of Shareholders
Vancouver, Canada. October 1, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, provided an update on the development plans for its lead compound, NVG-291, in three primary indications: multiple sclerosis, spinal cord injury […]